Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy and safety of atorvastatin and rosuvastatin in ischemic heart disease patients: A prospective study

Mariam Maqsood¹, Saleha Sadeeqa² , Maqsood Ahmad¹, Hafsa Afzal²

¹Lahore Pharmacy College, Lahore Medical and Dental College; ²Institute of Pharmacy, Lahore College for Women University, Lahore, Pakistan.

For correspondence:- Saleha Sadeeqa Email: salehasadeeqa@gmail.com

Accepted: 21 June 2019 Published: 29 July 2019

Citation: Maqsood M, Sadeeqa S, Ahmad M, Afzal H. Efficacy and safety of atorvastatin and rosuvastatin in ischemic heart disease patients: A prospective study. Trop J Pharm Res 2019; 18(7):1533-1538 doi: 10.4314/tjpr.v18i7.25

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To compare the safety and efficacy of two commonly used statins namely; atorvastatin and rosuvastatin, and determine the efficiency of CoQ10 in the reversal of statin-induced myopathy.

Methods: An investigational study design was adopted using randomized trials involving patients suffering from ischemic heart disease and receiving either atorvastatin or rosuvastatin. The study was conducted at Punjab Institute of Cardiology, Lahore, Pakistan during the period, November 2016 - February 2017. A total number of 95 male and female patients, between the ages of 40 and 80 years, were selected. Their blood samples were analyzed for lipid profile, total cholesterol, serum high-density lipoprotein-cholesterol (HDL-C), serum triglycerides, low-density lipoproteins-cholesterol (LDL-C) and total cholesterol/HDL-C ratio.

Results: Gender and dose showed significant correlation with creatine phosphokinase (CPK) levels, (p = 0.001) and (p > 0.001), respectively. The patients using rosuvastatin 20 mg had a higher risk of developing myopathy than those treated with atorvastatin 40 mg (p = 0.023), while atorvastatin 20 mg patients were more prone to induce myopathy than 10 mg (p = 0.001) recipients. Atorvastatin 20 mg produced higher CPK levels than rosuvastatin 10 mg (p = 0.002). A substantial increase in CPK levels was found with rosuvastatin 20 mg and atorvastatin 20 mg usage (p > 0.001). It was observed that rosuvastatin 20 mg significantly increased the risk of myopathy compared to atorvastatin 10 mg (p > 0.001). However, rosuvastatin 20 mg/day considerably reduced the blood cholesterol as compared to atorvastatin 10mg/day (p = 0.001). CPK levels reduced significantly following treatment with CoQ10 (p = 0.022).

Conclusion: Rosuvastatin users are more prone to the risk of myopathy, myalgic symptoms and rise in CPK levels than atorvastatin users, and these effects are dose related. CoQ10 is effective in lowering CPK levels and reversing myalgia.

Keywords: Statin, Myalgia, CoQ10, CPK, Atorvastatin, Rosuvastatin